The sensing of microbial genetic material by leukocytes often elicits beneficial pro-inflammatory cytokines, but dysregulated responses can cause severe pathogenesis. Genome-wide association studies have linked the gene encoding phospholipase D3 (PLD3) to Alzheimer's disease and have linked PLD4 to rheumatoid arthritis and systemic sclerosis. PLD3 and PLD4 are endolysosomal proteins whose functions are obscure. Here, PLD4-deficient mice were found to have an inflammatory disease, marked by elevated levels of interferon-γ (IFN-γ ) and splenomegaly. These phenotypes were traced to altered responsiveness of PLD4-deficient dendritic cells to ligands of the single-stranded DNA sensor TLR9. Macrophages from PLD3-deficient mice also had exaggerated TLR9 responses. Although PLD4 and PLD3 were presumed to be phospholipases, we found that they are 5′ exonucleases, probably identical to spleen phosphodiesterase, that break down TLR9 ligands. Mice deficient in both PLD3 and PLD4 developed lethal liver inflammation in early life, which indicates that both enzymes are needed to regulate inflammatory cytokine responses via the degradation of nucleic acids.
L eukocytes carry conserved sensors for endocytosed DNA and RNA that trigger the production of pro-inflammatory cytokines. The ensuing inflammation can be beneficial for host defense against microorganisms, viruses and tumors but can also be pathogenic. The recognition of nucleic acids by the host triggers production of the type I interferons IFN-α and IFN-β and inflammatory cytokines such as interleukin-6 (IL-6) and IL-12 1, 2 . Viral, bacterial or host DNA and RNA can be recognized, depending on the sequence motifs, concentration, intracellular localization and rate of degradation. One class of sensors resides in endosomes and includes TLR3, TLR7, TLR8, TLR9 and TLR13, which recognize double-stranded RNA (dsRNA), singlestranded RNA (ssRNA), ssRNA, ssDNA carrying unmethylated CpG motifs, and bacterial 23 S RNA, respectively. A second class of sensors resides in the cytoplasm: RNA helicase 'RIG-I-like receptors' recognize uncapped dsRNA, whereas cGAS ('cyclic GMP-AMP synthase') and AIM2 ('absent in melanoma 2') are cytoplasmic sensors of DNA. These sensors are believed to favor recognition of foreign genetic material, because host DNA and RNA often have distinct sequence abundances and modifications, are localized away from the sensors or are degraded in a more efficient or organized manner.
Evidence is mounting that regulation of the abundance of nucleic acids by nucleases prevents autoinflammatory and autoimmune diseases driven by sensors of nucleic acids 3 . Deficiency in Dnase1 or Dnase1L3 (which encode DNAses) leads to systemic lupus erythematosus in both humans and mice [4] [5] [6] . In mice, Dnase2a deficiency leads to a lethal interferon-mediated disease, while patients deficient in DNASE2a exhibit autoinflammatory anemia, kidney and joint disease 7, 8 . Patients with deficiency in TREX1 develop Aicardi-Goutières syndrome, while Trex1-deficient mice develop a lethal cardiomyopathy inflammatory disease [9] [10] [11] . Prevention of the abnormal accumulation of host nucleic acid in different tissues and cellular compartments is thus performed by an array of enzymes with non-redundant functions.
Proteins of the phospholipase D (PLD) family share a catalyticsite sequence signature (HxxKxxxxD, where 'x' indicates any amino acid; the 'HKD motif ') that is present in the cytosolic phospholipases PLD1 and PLD2, but most family members have distinct functions and intracellular localization [12] [13] [14] . PLD3 and PLD4 are glycosylated type II transmembrane proteins located in endolysosomes [15] [16] [17] and reside in subcellular compartments distinct from those in which most other members of the PLD family reside. Studies have linked PLD4 polymorphisms to systemic sclerosis and rheumatoid PLD3 and PLD4 are single-stranded acid exonucleases that regulate endosomal nucleic-acid sensing ' interferon signature' in Pld4 -/mice, as > 40 of the 109 genes whose expression was significantly elevated in Pld4 -/-Rag1 -/splenocytes (relative to their expression in Rag1 -/splenocytes) are known to be inducible by IFN-γ or type I interferons ( Fig. 1k and Supplementary  Table 1 ). Expression of Il12b, Cxcl9 and Il10 was also significantly elevated in Pld4 -/-Rag1 -/splenocytes. Of the 33 genes downregulated in Pld4 -/-Rag1 -/mice, some are known to be suppressed by interferons, but most are NK cell-specific genes, consistent with the lower number of NK cells in the spleen of Pld4 -/mice and Pld4 -/-Rag1 -/mice.
Certain features of the phenotype of Pld4 -/mice resembled the human disease macrophage-activation syndrome, which can be mimicked in mice by repeated challenge with ligands of TLR9 30 . To assess the role of TLR9 in the PLD4-deficient phenotype, we bred Tlr9 -/-Pld4 -/mice. Notably, analysis of these mice indicated that all of the abnormalities of the PLD4-deficient mice that we assessed were dependent on TLR9, including splenomegaly, upregulation of MHC class II expression and alterations in the number of monocytes, platelets, NK cells and B-1 cells (Fig. 1c ,f-j). In contrast, combined deficiency in both PLD4 and IFN-γ reversed only a subset of the phenotypic features associated with PLD4 deficiency (Fig. 1c ,f,g), which suggested that IFN-γ production by Pld4 -/mice was secondary to triggering of TLR9. Histological analysis of Pld4 -/livers revealed a TLR9-dependent increase in the frequency and size of CD68 + macrophages, consistent with mild liver inflammation ( Fig. 2) . Overall, these results suggested that the main effects of PLD4 deficiency stemmed from enhanced or dysregulated recognition of ssDNA by TLR9 in endolysosomes.
The finding that Pld4 -/mice had excessive TLR9-driven production of IFN-γ and Il12b mRNA suggested that activation of CD8 + DCs might be dysregulated in these mice. Secretion of IL-12 by CD8 + DCs is known to stimulate IFN-γ production, particularly by NK cells 31 . Sorted PLD4-deficient splenic DCs were found to produce more IL-12p70 and IL-6 in response to two TLR9 ligands, VACV70 and 2216PS (an A-type CpG oligodeoxynucleotide (ODN)), than did their PLD4-sufficient counterparts; however, the responses of these cells to the B-type CpG ODN 1668PS were similar ( Fig. 1l,m) . 1668PS is fully modified by phosphorothioate (PS) linkages, 2216PS is partially modified by PS linkages and VACV70 is unmodified double-stranded DNA (dsDNA) containing CpG motifs ( Table 1 ). In addition, VACV70 elicited IFN-λ responses in CD8 + DCs through the STING cytoplasmic DNA-sensing pathway, but 1668PS and 2216PS did not, and this did not differ in wildtype cells versus PLD4-deficient cells ( Fig. 1n and Supplementary  Fig. 3a,b ). IFN-γ signals are known to promote IL-12 responses 32 ; however, sorted CD8 + DCs isolated from Pld4 -/-Ifng -/mice also showed elevated IL-12 responses to TLR9 stimuli, relative to Ifng -/-CD8 + DCs ( Supplementary Fig. 3c ). Pld4 -/-CD8 -CD11b hi splenic DCs also had enhanced IL-6 and IL-12 responses relative to Pld4 fl/fl controls, especially to VACV70 ( Supplementary Fig. 3d ). These 13, 15, 6, 6, 4, 4, 9, 9, 8 and 5 mice per genotype, top to bottom); results are presented relative to those of PLD4-sufficient controls carried out contemporaneously. d,e, Plasma cytokine concentration of IFN-γ (d) and CXCL10 (e) in Pld4 fl/fl and Pld4 -/mice (key in e) 7 weeks of age (left half; n = 8 per group) or 32 weeks of age or more (32 weeks + ; n = 9 per group). f-j, Frequency of splenic NK cells among spleen cells (f) and peritoneal B-1 cells among CD19 + cells (g), spleen weight (h), and quantification of monocytes (i) and blood platelets (PLT) (j) in mice of various genotypes (left margin: n = 12, 12, 4, 4, 9 and 9 mice per group (top to bottom in f,g); n = 9 mice per group (h) or n = 5 mice per group (i,j)). k, Sequencing analysis of mRNA (genes, left margin) in splenocytes from Pld4 -/-Rag1 -/mice (Pld4 -/-) and Pld4 +/+ Rag1 -/mice (Pld4 +/+ ) (above plots; n = 3 per group (1-3 above columns)), showing the significance (P values, right margin; false-discovery rate, ≤ 0.05, calculated using edgeR) of the change in expression (fold values; far right and key). l-n, IL-12p70 response (l), IL-6 response (m) and IFN-λ response (n) of sorted splenic Pld4 fl/fl and Pld4 -/-(key) CD8 + DCs to various TLR9 ligands or medium (left margin). Each symbol (a,c-j,l-n) represents an individual mouse (a,c-j) or culture (l-n); small horizontal lines (a,c-j) indicate the mean ( ± s.e.m. (a,d-g), geometric s.d. (c) or linear s.d. (h-j)). P values (in plots), unpaired two-tailed t-test. Data are from at least two independent experiments in l-n (mean ± s.d. of triplicate cultures).
results supported the notion that Pld4 -/-CD8 + DCs had enhanced cytokine responses to at least some TLR9 ligands.
PLD4 and PLD3 are single-stranded 5′ exonucleases. The results reported above suggested a role for PLD4 in the processing of TLR9 ligands. To test for nuclease activity, we engineered expression of recombinant soluble mouse PLD4 by substituting a secretion signal peptide for the amino-terminal transmembrane and cytoplasmic tail. Using various DNA substrates ( Fig. 3a) , we then assessed the activity of purified recombinant mouse PLD4. PLD4 degraded a 55-nucleotide (nt) ssDNA (Fig. 3b , lane 2) but not a dsDNA version of the same sequence (Fig. 3b , lane 6). When paired with shorter ssDNAs complementary with the 5′ or 3′ end, PLD4 degraded only a substrate with an unpaired 5′ end (Fig. 3b, lane 4) , indicative of 5′ -to-3′ ssDNA-exonuclease activity but not 3′ -to-5′ ssDNA-exonuclease activity, and demonstrated a lack of endonuclease activity (Fig. 3b , lane 5). PLD4 protein carrying histidine-to-alanine substitutions in both HKD motifs (PLD4-AA) lacked detectable enzymatic activity (Fig. 3b, lanes 7-11) . PLD4 cleaved only substrates that lacked phosphorylated 5′ ends and was unaffected by 3′ (Fig. 3c , lanes 4 and 6). As predicted for an endosomal nuclease, the reaction was most efficient at pH < 6 but was still detectable at pH 7 ( Fig. 3d ). Parallel experiments with mouse PLD3 revealed a similar profile of substrate specificity and an acidic pH optimum ( Fig. 3e-g ). We concluded that PLD3 and PLD4 are 5′ exonucleases that are able to cleave ssDNA.
PLD3 and PLD4 appear to be classic spleen phosphodiesterases.
The enzymatic properties of PLD4 and PLD3 that we observed were reminiscent of the activity previously described as 'spleen acid exonuclease' or 'spleen phosphodiesterase' 28, 33 (Enzyme Commission registry number 3.1.16.1, http://www.sbcs.qmul.ac.uk/iubmb/ enzyme/EC3/1/16/1.html). We therefore directly compared PLD3 and PLD4 with a commercial preparation of bovine spleen phosphodiesterase (as a positive control) through the use of a diagnostic assay that measured their ability to digest GpA or ApG dinucleotides. Digestion was readily tracked by spectroscopy via the release and loss of adenosine, which is deaminated in a coupled assay 34 . Mouse and human recombinant soluble PLD3 and PLD4 specifically cleaved the phosphodiester bond between the phosphate and the second nucleotide, which matched the activity described for bovine spleen exonuclease, but PLD4-AA did not ( Fig. 3h ). Snake venom phosphodiesterase served as a control for possible cleavage at the upstream phosphodiester bond, which leaves 5′ phosphorylated mononucleotides. The results indicated that digestion by PLD3 or PLD4 generated 3′ mononucleotides and nucleosides from short oligonucleotide substrates. The commercial reagent phosphodiesterase II was further purified by size exclusion to diminish complexity of the sample, and the enzymatically active fractions were subjected to analysis by trypsin-liquid chromatography-mass , c (f) or d (g), but with PLD3 or PLD3-AA (10 nM) (above gels) instead of PLD4 or PLD4-AA. In b,e, the images are cropped between lanes 1 and 2 to eliminate additional undigested control lanes. h, Release of adenosine by the digestion of dinucleotide GpA (left) or ApG (right), as described 34 , by mouse (m) or human (h) PLD3 or PLD4 or mouse PLD4-AA, snake venom phosphodiesterase I (PDI (venom)) or calf spleen phosphodiesterase II (spleen exonuclease) (PDII (bovine)), presented as the optical density at 265 nm (OD 265 ). i, Electrophoresis of the products of the digestion of various PS-linked substrate ODNs (above gels ( Table 1) spectrometry. Six peptides unique to bovine PLD3 were identified ( Supplementary Fig. 4a,b ). Other proteins, however, were also identified ( Supplementary Fig. 4c ), consistent with low specific activity of the commercial preparation in the dinucleotide-cleavage assay ( Fig. 3h ). We concluded that PLD3 and PLD4 had activities indistinguishable from classic spleen acid exonuclease.
PLD3 and PLD4 can degrade PS-linked CpG agonists of TLR9
in vitro. PS linkages are often used in synthetic ODNs to hinder their digestion by nucleases. The B-type CpG ODNs 2006PS and 1668PS are fully PS modified. They stimulate TLR9 'preferentially' through the transcription factor NF-κ B pathway to produce cytokines such as IL-6 and IL-12 35 . The A-type CpG ODN 2216PS is a potent inducer of IFN-α and has an internal palindromic sequence composed of phosphodiester-linked nucleotides flanked by strings of PS-modified guanine nucleotides known to form unusual secondary structures 35 . Human and mouse PLD3 and PLD4 were able to digest the B-type CpG ODNs 2006PS and 1668PS despite their PS linkages ( Fig. 3i ), albeit 20-50 times less efficiently than their digestion of versions with phosphodiester bonds ( Supplementary  Fig. 5a ,c), but they failed to digest 2216 or 2216PS ( Fig. 2i , right; Supplementary Fig. 5b,d ). We concluded that PLD3 and PLD4 digested single-stranded ODNs, including those with PS linkages, but were blocked by features of A-type CpG ODNs (probably their secondary structure).
PLD3 and PLD4 limit cellular responses to exogenous TLR9 ligands.
To assess PLD3's function and potential redundancy with PLD4, we used CRISPR-Cas9-mediated mutagenesis of mouse zygotes to generate Pld3 strains lacking PLD3 protein ( Supplementary Fig. 1j ,k). Pld3 -/macrophages elicited with thioglycolate ('thioglycolate-elicited' macrophages) expressed more IL-6 in response to 2216PS than did their wild-type or Pld4 -/counterparts ( Fig. 4a ). The enhanced response was observed with macrophages from multiple founder lines, but not with macrophages from the wild-type or Pld3 +/littermates. In contrast, the responses of Pld3 -/macrophages to the TLR4 agonist lipopolysaccharide were similar to those of wild-type and Pld4 -/macrophages ( Fig. 4b ).
RNA-expression analysis revealed that wild-type thioglycolate-elicited macrophages had high expression of Pld3 and low expression of Pld4, whereas wild-type DCs showed an opposite pattern of expression ( Fig. 4c,d ). Pld3 -/mice lacked other phenotypic characteristics observed in Pld4 -/mice and had a spleen size, proportion of splenic NK cells and surface expression of MHC class II on resident peritoneal macrophages similar to that of their heterozygous (control) littermates ( Supplementary Fig. 1l-n) , and the responses of DCs cultured with cytokine FLT3L to TLR9 ligands were unchanged ( Supplementary Fig. 6f ). The functional redundancy and distinct expression profiles were thus consistent with the altered responses of Pld3 -/thioglycolate-elicited macrophages and those of Pld4 -/-CD8 + DCs. Recombinant PLD3 was unable to degrade the TLR9 ligand 2216PS in vitro ( Fig. 3i and Supplementary Fig. 5d ), so it was unexpected that Pld3 -/thioglycolate-elicited macrophages had an enhanced IL-6 response to 2216PS (Fig. 4a,b ). TLR9 responses to 2216PS require its cleavage by DNase II in the palindromic phosphodiester-linked central region 36 . As DNAse II cleaves dsDNA or palindromic ssDNA and thus creates fragments with IL-6 (ng/ml) A3′10PS   0  5  10 15 20 IL-12p70 (ng/ml) unphosphorylated 5′ ends and 3′ phosphates, we hypothesized that DNAse II-cleaved 2216PS fragments should be naturally degraded by PLD3 or PLD4. We therefore tested the ability of a series of synthesized fragments of 2216 or 2216PS (Fig. 5a ) to stimulate DCs cultured with FLT3L and to stimulate PLD3-or PLD4-deficient thioglycolate-elicited macrophages ( Fig. 5b-e ). The Pld4 -/-DCs and . P values (in plot), unpaired two-tailed t-test. g, IL-6 in supernatants of bone marrow-derived macrophages isolated from 19-day-old C57BL/6, Pld3 -/-Pld4 -/-, Pld3 -/or Pld4 -/mice (key), assessed after stimulation in vitro with various TLR agonists (horizontal axis). Each symbol represents an individual culture. NS, not significant (P > 0.05); *P < 0.05, * P < 0.01 and ***P < 0.001, C57BL/6 versus Pld3 -/-Pld4 -/-(unpaired two-tailed t-test). Data are representative of two experiments with similar results (mean and s.d. of triplicate cultures).
Pld3 -/macrophages showed enhanced responses to these shorter ligands, relative to the responses of their PLD3-or PLD4-sufficient counterparts ( Fig. 5b-e ). When packaged in the transfection reagent Lyovec, the same ODN ligands elicited similar strong responses in both wild-type DCs and PLD4-deficient DCs ( Supplementary Fig.  6a,b) , which suggested that ligand stability, rather than TLR9 signaling, was affected by PLD4 deficiency and could be bypassed through the use of this reagent. Interestingly, PLD3-deficient thioglycolate-elicited macrophages still had enhanced responses to Lyovec complexes of 2216 subfragments ( Supplementary Fig. 6c ), which indicated some cell type-specific differences. In both DCs and macrophages, responses to the ODNs 1668PS and 2216PS were dependent on TLR9 ( Fig. 5b-d) . The enhanced bioactivity of particular CpG fragments in PLD3-or PLD4-deficient cells correlated with their sensitivity to PLD3 and PLD4 in vitro (Fig. 5f) .
To enable analysis of the function of PLD3 and PLD4 in human cells, we generated PLD3-deficient clones of the cell line HEK-Blue hTLR9 (human embryonic kidney cells that express human TLR9) by CRISPR-Cas9 technology. Independent PLD3-deficient clones had greatly enhanced responses to 2216PS and its synthetic fragments, as well as to a phosphodiester form of the B-type CpG 2006 relative to unmutated HEK-Blue hTLR9 cells ( Fig. 5g and Supplementary Fig. 6d,e ). Reconstitution of those cells with PLD4 inhibited the response to the baseline level, whereas reconstitution with PLD4-AA did not (Fig. 5g ), which suggested that nuclease activity was needed to limit the response. Enhanced stability of TLR9 ligands in cells lacking PLD3 and PLD4. To assess the degradation of ODNs in vivo, we stimulated wild-type or mutant thioglycolate-elicited macrophages with ODN 2216 carrying a 3′ biotin tag; after 3.5 h or 8 h, we recovered ODNs from cell lysates through the use of streptavidin beads and visualized them by 32 P end-labeling. This analysis revealed that the 2216-biotin fragments that demonstrated enhanced stimulatory activity in Pld3 -/macrophages and Pld4 -/-DCs were degraded less in lysates of Pld3 -/macrophages than in those of PLD3-sufficient macrophages, which had shorter species composed mainly of the poly(G) 3′ end (< 10 nt) (Fig. 5h ). The degradation pattern in Unc93b 3d/3d macrophages, which lack signaling via TLR3, TLR7 and TLR9 37 , was identical to that of wild-type macrophages, which indicated that signaling via TLR9 was not required for enzymatic degradation by PLD3. Similar results were obtained for PLD3 -/-HEK-Blue hTLR9 cells 'fed' 2216-biotin, in which DNA fragments of 10-15 nt were more abundant than in unmutated HEK-Blue hTLR9 cells, and these DNA fragments were specifically depleted in cells reconstituted with PLD4 or PLD3 but not in those reconstituted with the mutant PLD4-AA or PLD3-AA (Fig. 5i ). We concluded that PLD3 and PLD4 had redundant exonuclease function that was able to limit TLR9 responses to CpG ODNs, particularly those lacking PS linkages, by reducing the concentration of ssDNA able to stimulate TLR9, and that these activities were similar in cells of humans and mice.
PLD3 and PLD4 prevent a lethal hepatic autoinflammatory disease. The overlapping enzymatic activities of PLD3 and PLD4 and their co-expression in macrophage subsets prompted us to interbreed Pld3 -/mice and Pld4 -/mice to generate mice deficient in both enzymes. No mice deficient in both genes survived to the age of weaning ( Supplementary Fig. 7a ). Pld3 -/-Pld4 -/mice of each sex were identified, but these mice were undersized relative to the size of their heterozygous littermates, and they died between 12 d of age and 21 d of age with severe liver inflammation (Fig. 6a-d and Supplementary Fig. 7b,c) . The liver of Pld3 -/-Pld4 -/mice showed macroscopic white areas of necrosis ( Supplementary Fig. 7c ), with regions of vesicular steatosis (Fig. 6a) , hemophagocytosis ( Fig. 6b ) and multinucleated hepatocytes (Fig. 6c) . Notably, only a single allele of either Pld3 or Pld4 was needed to allow survival and to prevent the substantial liver pathology ( Fig. 6d and Supplementary Table  2 ). Although CD68 + myeloid cells were more prevalent in the liver of 16-day-old Pld3 +/-Pld4 -/mice than in that of their Pld3 +/-Pld4 +/or Pld3 -/-Pld4 +/littermates, the liver of Pld3 -/-Pld4 -/mice demonstrated extensive infiltration by CD68 + myeloid cells (Fig. 6d) . Serum from Pld3 -/-Pld4 -/mice had a higher concentration of ferritin, the cytokines IL-6, IL-10, TNF, IFN-γ , the chemokines CXCL10, MCP3 (CCL7) and MCP1 (CCL2), than that of serum from mice of the same age expressing one or more copies of Pld3 or Pld4, whereas the concentration of IFN-α and IL-1α was not significantly elevated in the Pld3 -/-Pld4 -/mice (Fig. 6e,f) . We inferred that neonatal mice needed PLD3 and PLD4 to prevent an inflammatory disease consistent with hemophagocytic lymphohistiocytosis. Analysis of the responses of Pld3 -/-Pld4 -/bone marrow-derived macrophages to TLR9 ligands revealed elevated secretion of IL-6 in response to 2216 subfragments, VACV70 or 1668 (DNA form), but their responses to 1668PS, the synthetic imidazoquinoline resiquimod (R848, a TLR8 agonist) and lipopolysaccharide were similar to those of their wild-type or singly deficient counterparts (Fig. 6g ). As both Pld3 and Pld4 were expressed in bone marrow-derived macrophages (Fig. 4c) , the enhanced responses to specific TLR9 ligands occurred when both genes were absent but not when either gene was present (Fig. 6g) . Pld3 -/-Pld4 -/bone marrow failed to generate DCs in culture with FLT3L, which suggested either that the ongoing inflammation was affecting precursors of DCs in the bone marrow or that both proteins were required for the in vitro FLT3Ldriven development of DCs.
PLD3 and PLD4 in hematopoietic cells prevent autoinflammation.
To determine whether the immune system itself was the driver of the lethal inflammation in Pld3 -/-Pld4 -/mice, we transplanted bone marrow from 19-day-old Pld3 +/-Pld4 -/-, Pld3 -/-Pld4 +/or Pld3 -/-Pld4 -/littermate donors into lethally irradiated 6-week-old wildtype CD45.1 + recipients. At 8 weeks after transfer, blood analysis revealed low platelet counts, anemia, elevated reticulocytes and leukopenia in the recipients that received Pld3 -/-Pld4 -/bone marrow but not in recipients given bone marrow from littermates with a single wild-type allele of either Pld3 or Pld4 (Fig. 7a ). Despite the overt splenomegaly of recipients of Pld3 -/-Pld4 -/bone marrow, the number of splenic leukocytes recovered after erythrocyte lysis was lower in recipients of Pld3 -/-Pld4 -/bone marrow than in mice receiving bone marrow expressing either PLD3 or PLD4 (Fig. 7b ). Flow cytometry of CD45.2 + splenocytes revealed a marked reduction in the proportion and number of B cells when both Pld3 and Pld4 were absent, relative to their abundance when either gene was present (Fig. 7c,d) . The total number of TCRβ + CD4 + or CD8 + T cells was also lower in the spleen of recipients of Pld3 -/-Pld4 -/bone marrow than in that of mice receiving bone marrow expressing either PLD3 or PLD4 (Fig. 7e) ; however, the majority of those CD8 + T cells exhibited an activated phenotype (CD44 hi CD62L lo ), and very few naive CD8 + T cells (CD44 lo CD62L + ) were present (Fig. 7f,g) . Consistent with the disease observed in Pld3 -/-Pld4 -/mice, recipients of Pld3 -/-Pld4 -/bone marrow had elevated expression of MHC class II (with CD86 expression similar to that of controls) on peritoneal macrophages, a greater abundance of blood monocytes, and a higher concentration of the cytokines CXCL10, IFN-γ , MCP3, IL-6 in serum compared to recipients of bone marrow in which either PLD3 or PLD4 was present, but IFN-α was not detected in serum ( Supplementary Fig. 7d-k) . We concluded that both PLD3 and PLD4 limited autoinflammation and that a single wild-type allele of either Pld3 or Pld4 was able to prevent the development of the inflammatory disease transferred via hematopoietic stem cells.
Discussion
We have presented evidence that the endolysosomal proteins PLD3 and PLD4 trimmed the 5′ end of single-stranded ODNs and thus degraded them and limited their ability to stimulate TLR9. Consistent with that conclusion, PLD3 and PLD4 are most active at an acidic pH (5-5.5) and are localized to endolysosomes [15] [16] [17] . Notably, neither enzyme seems to have phospholipase activity 25, 38 .
Human genome-wide association studies have linked polymorphisms of PLD3 and PLD4 to inflammatory diseases. In animals, spontaneous Pld4-null mutations have been linked to skin disease and runting. A mouse mutant identified on the BALB/c background strain thss ('thin hair with small size') seems to have abnormalities distinct from those of PLD4 deficiency on the C57BL/6 background that we have investigated here (http://www.informatics.jax.org/ reference/J:171492). A spontaneous PLD4-null mutation occurred in a herd of cattle, whereby homozygous calves were runts with skin lesions, respiratory-and digestive-tract inflammation and mild anemia 39 . It will be of interest to determine if these phenotypes are also connected to activation of TLR9.
The similarities in the enzymatic activities of PLD3 and those of PLD4 and their partly overlapping expression patterns would suggest that they have redundant functions in key cell types. The RNA-profiling data indicated that PLD4 had a narrow tissue distribution, with high levels in DCs and myeloid cells, whereas PLD3 had a broad distribution and seemed to digest artificial substrates with greater efficiency than did PLD4. PLD3 enters the lysosome by an unusual sorting and ubiquitination pathway regulated by the ESCRT complex 17 , and other PLD3-deficient mice reportedly show no altered phenotype except for effects on the morphology of the lysosomal system 16 . The phenotype of our Pld3 -/mice also seemed more benign than that of Pld4 -/mice. This observation might be explained by the high levels of PLD4 normally present in cells with high expression of TLR9. Although Pld4 -/mice had a relatively mild form of macrophage-activation syndrome, the residual PLD3 in myeloid cells probably provided protection from more-severe disease, as a single allele of either Pld3 or Pld4 protects mice against lethal inflammation early in life.
Nucleic-acid sensors are endowed with a restricted fine specificity and affinity for ligands. Responses are limited by the quantity of ligands available and their intracellular localization. PLD3 and PLD4 provide DNAse activity directed against ssDNA in endolysosomes; it is probably no coincidence that they reside in the same compartment as active TLR9. Notably, PLD3 and PLD4 required DNA substrates with a non-phosphorylated 5′ end and the absence of secondary structure. Nucleic acids with such features are relatively rare in nature but are generated efficiently in endolysosomes by DNAse II, which cleaves dsDNA down to ssDNA fragments of ~10 nt carrying 3′ phosphate and 5′ hydroxyl groups 36 . DNAse II is also needed to process DNA hairpins, such as A-type CpG ligands, for recognition by TLR9. Published work has indicated that TLR9 has two binding sites: one that binds ssDNA with a CpG motif and another that binds short ssDNA carrying a 5′ hydroxyl group 40 . Thus, the short stimulatory ligands that TLR9 is predicted to encounter should also be good substrates for PLD3 and PLD4. Endosomal build-up of such short ssDNA in the absence of PLD3 or PLD4 would probably not trigger interferon responses mediated by STING-cGAS, as ssDNA greater than 21 nt in length is required and this might be prevented by the presence of TREX1 in the cytoplasm 41, 42 .
Although mild, the phenotype of Pld4 -/mice is reminiscent of human macrophage-activation syndrome, which is associated with elevated concentrations of IFN-γ , IL-12, CXCL9 and CXCL10, a low number of NK cells and an increase in liver CD68 + cells and can be mimicked in mice by repeated injection of a TLR9 ligand 3, 30, 43, 44 . Notably, all of the features of the phenotype of Pld4 -/mice were absent from mice that also lacked TLR9, consistent with the hypothesis that defective degradation of ligands for TLR9 is central to the phenotype. That was further supported by evidence showing that Pld3 -/macrophages and HEK293-Blue hTLR9 cells had exaggerated responses to particular ssDNA ligands of TLR9. Several features of the disease transferred via Pld3 -/-Pld4 -/bone marrow into wildtype recipients mimicked dysregulated TLR9 signaling 45 . Mice that receive stem cells expressing a mutant TLR9 that does not require proteolytic activation or traffic normally to endolysosomes succumb to a DC-driven fatal inflammation characterized by profound anemia and a decreased abundance of splenic B cells 45 . The death of Pld3 -/-Pld4 -/mice in early life reflects the important role of PLD3 and PLD4 in limiting autoinflammation, and although we predict that TLR9 signaling is required for the disease, this needs to be addressed by further mouse breeding.
Beginning in infancy, the liver of children with primary hemophagocytic lymphohistiocytosis shows several features similar to that of Pld3 -/-Pld4 -/mice, including giant-cell hepatitis, steatosis, necrosis and the namesake hemophagocytosis 46 . The high concentrations of ferritin and cytokine in serum and extensive hepatic infiltration by CD68 + cells in Pld3 -/-Pld4 -/mice provide further similarities to primary hemophagocytic lymphohistiocytosis, although this disease is usually associated with mutations that result in defective cytotoxic granule contents of, or exocytosis from, NK cells and T cells 47 .
PS linkages are used in synthetic ODNs to hinder their digestion by nucleases. B-type CpG ODNs (such as 1668PS) that are fully modified by PS linkages could drive TLR9-mediated secretion of IL-6 and IL-12 from macrophages and DCs independently of PLD3 or PLD4. However, PS linkages are by no means strictly artificial and are widely present in nature in the DNA of bacteria 48 . The finding that PLD3 and PLD4 digested ODNs carrying PS linkages or strings of guanine residues more slowly than they digested host DNA might favor innate recognition of bacteria or viruses.
We found that PLD3 and PLD4 are 5′ exonucleases with properties strikingly similar to the enzymatic activity described many years ago as 'spleen acid exonuclease' 27, 28 . The bovine enzyme has an optimum pH of 5.5 and is specific for 5′ single strands; it has also been characterized as a non-processive nuclease that is inhibited by 5′ phosphate and generates 3′ -nucleotide monophosphate products 27, 49 . The degradation of ssDNA substrates by PLD3 and PLD4 was similarly non-processive and blocked by 5′ phosphate and generated 3′ nucleotide monophosphates, and the digestion was able to proceed to completion, generating mononucleotides and nucleosides, as does the spleen exonuclease 34 . Although the gene encoding spleen exonuclease has never been cloned, the enzymatic activity of spleen exonuclease has been described in humans, rats, cows and pigs, whose predicted PLD3 proteins are highly conserved (93-96% identical between species). The similarities among bovine, mouse and human PLD3 in enzymatic features and the considerable amino-acid identity suggest that PLD3 might have activity identical to the spleen-phosphodiesterase activity previously described, although PLD4 cannot be excluded as a contributor to this activity, as it is also conserved among these species (> 70% identical) and has a very similar enzymatic activity.
Methods
Methods, including statements of data availability and any associated accession codes and references, are available at https://doi. org/10.1038/s41590-018-0179-y. A description of all covariates tested A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons A full description of the statistics including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
nature research | reporting summary
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted Our web collection on statistics for biologists may be useful.
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Data collection
Flow sorting data was collected using BD Diva software. Flow cytometry data was collected LSRII flow cytometer. Serum cytokine analysis using FlowCytomix beads was acquired by LSRII flow cytometer. Cytokine ELISA data was collected using Softmax Pro.
Data analysis
Flow cytometry data was analyzed using FloJo software. RNA-seq data was analyzed using either Salmon, (Figure 1k and Supplementary  Table 1 , or Degust (http://degust.erc.monash.edu/ 790 Version: 3.1.0) for Figure 4d . CD68+ macrophages were enumerated from images using FIJI (Image J version 2.0.0-rc-65/1.5u). Serum cytokine analysis using FlowCytomix beads was acquired by LSRII flow cytometer and mean fluorescence values generated using FlowJo. Mean fluorescence values were converted to pg/ml using standards and calculations using Prism standard curve interpolation.
For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers upon request. We strongly encourage code deposition in a community repository (e.g. GitHub 
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
Sample size
In determining the number of mice to be used in these experiments, we referred to " To provide a p<0.05 with 80% power in comparing two means with similar sample sizes and normal distributions, the formula used is: n= 20(S.D.)^2 where n, S.D., and d are the sample size, standard deviation of d^2 measurements and the differences in the experimental and control means. The referenced text notes that, for added stringency, 20 would be replaced by 30. Because in measurements of relevant parameters of leukocyte function the standard deviation approximates the mean, in order to detect a two-fold difference between experimental groups a sample size of 5-7 mice is needed per group. Usually, additional redundancy was added, such as independent experiments. We also carried out independent comparisons of Pld4+/-vs Pld4-/-littermates, Pld3+/-vs Pld3-/-littermates, and separate analysis of cohorts of Pld4-fl/fl vs age matched Pld4-/-, or Tlr9-/-vs Tlr9-/-Pld4-/-mice. figure) . Blood monocytes, IFNg and CXCL10 levels from blood were determined from age and sex matched animals with two different age ranges. Each point is derived from an individual animal. RNA was isolated from three different RAG1-/-(WT) or Pld4-/-RAG1-/-(KO) spleens and analyzed for gene expression. Splenic DCs were sorted and stimulated in triplicate cultures. These experiments were performed 4 times with similar results. Figure 2 . Analysis of CD68+ macrophages in frozen liver sections was performed on a total of 3 Pld4fl/fl, 4 Pld4-/-, 4Tlr9-/-and 4Tlr9-/-Pld4-/mice. Figure 3 . DNA or RNA oligonucleotides were digested with PLD4 or PLD3 proteins at least 4 times with similar results. Digestion of dinucleotide substrates with recombinant PLD3 or PLD4 and commercial phosphodiesterases was performed twice. Figure 4 . Peritoneal macrophages from Pld3-/-and control mice were plated in triplicate and each experiment performed at least 3 times. Spleen weight, NK cell proportions, and MHCII levels of macrophages of Pld3-/-and control mice was performed twice with similar results, with a single experiment shown in Fig S1l- n. Figure 5 FLT3L DC cultures and thioglycolate elicited macrophages of each genotype were plated in triplicates and stimulated with various 2216 subfragments. These experiments were performed at least 4 times with similar results (DC and macrophages) and 3 times with HEK293 PLD3 deficient cells. (h) Recovery and identification of 2216 fragments from macrophage lysates by electrophoresis was performed twice. The similar recovery experiment (i) using HEK293 PLD3 deficient line with or without reconstitution with PLD3 or PLD4 proteins was performed once. Figure 6 . Six Pld3-/-Pld4-/-animals were identified and a summary table outlining liver pathology for these animals is given in Supplementary Table 2 . Sera from a total of 12 Pld3-/-Pld4-/-animals was tested for cytokines and compared to 10 C57BL/6, and ranges of 5-7 each littermate genotype controls. Bone marrow macrophages from control or Pld3-/-Pld4-/-were plated in triplicate and stimulated with various TLR ligands. This experiment was repeated three times with similar results. A total of four individual sera from Pld3-/-Pld4-/-animals were compared with controls for ferritin levels in a single elisa. Figure 7 . Blood, spleen data from individual recipients 8 weeks after receiving bone marrow from Pld3-/-Pld4-/-mice or littermate controls. This experiment was done once.
Data exclusions
Randomization Both male and female animals of either Pld4fl/fl, Pld4-/-, C57BL/6, Tlr9-/-Pld4-/-, Tlr9-/-, Pld3-/-and Pld3-/-Pld4-/-genotypes were used in experiments. They were always age and sex matched with each other in each experiment. In some experiments, Pld3+/-Pld4+/-, Pld3-/-Pld4+/or Pld3+/-Pld4-/-genotypes (littermates) were used as controls for Pld3-/-Pld4-/-animals (not always sex matched).
Blinding
Genotypes were blinded in the liver histology pathology analysis summarized in Supplementary Table 2 . Genotypes were not blinded in the other experiments because the quantitative data obtained were not subject to observer bias.
Reporting for specific materials, systems and methods 
Validation
Pld4 mAb staining was confirmed for specificity by staining cells from Pld4-/-compared to Pld4 WT mice.
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Cell line source(s)
The eukaryotic cell line 293EBNA was used to generate recombinant soluble PLD3 and PLD4 in this study. This cell line was purchased from Invitrogen. HEK293 Blue hTLR9 cells were purchased from Invivogen.
Authentication
The 293EBNA cell line was grown in media containing 0.5mg/ml G418. The HEK293 Blue hTLR9 cell line responded to 2006 PS TLR9 stimuli by the production of SEAP as described by Invivogen. No genetic authentication was performed. PLD3 deficient clones generated from parental HEK293 Blue hTLR9 cell line were confirmed by sequencing of PCR products derived from genomic DNA.
Mycoplasma contamination
The 293 EBNA cell line and the HEK293 Blue hTLR9 cell line have not been tested for mycoplasma.
Commonly misidentified lines (See ICLAC register)
The 293 EBNA cell line is a derivative of HEK293 cells listed in the commonly misidentified cell line database. Growth in G418 should maintain the EBNA episome to promote EBNA-1 mediated gene replication. This cell line was used to produce recombinant proteins that were later purified, so the genetic origin of the cell line should have little influence on the characteristics of the purified protein used. HEK293 Blue hTLR9 cell line was used to generate PLD3 deficient human cells that could be tested for TLR9 responses. The genetic origin of the cell line should have little influence on the interpretation of the results, as all sub-lines were derived from original parent line purchased from Invivogen.
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Laboratory animals
The following laboratory animal strains were used. Pld4-/-and Pld4fl/fl animals were generated in a 129/Ev strain ES cell and backcrossed to C57BL/6J. Pld3-/-mice were generated on the C57BL/6J background. Tlr9 deficient and Unc93b3d/3d mice were generated by ENU mutagenesis on the C57BL/6 background. The following mouse strains bred with Pld4-/-mice including B6.129S7-Rag1tm1Mom/J, B6.129P2-Lyz2tm1(cre)Ifo/J, B6.Cg-Tg(Itgax-cre)1-1Reiz/J, B6.129S7-Ifngtm1Ts/J, C57BL/6JTlr9M7Btlr/ Mmjax (CpG11) were from the Jackson Laboratory. Unc93b3d/3d mice were obtained from Dr Bruce Beutler. Both male and female mice of ages ranging from 1.5 month to 8 months were used. Pld3-/-Pld4-/-mice or their littermates were generated by interbreeding the Pld3-/-and Pld4-/-lines and were studied between 12 and 21 days of age.
Wild animals
No wild animals were used.
Field-collected samples
No field-collected samples were used.
